On June 29, WuXi XDC rose 3.18% in regular trading, trading at 56.9 HKD/share, with turnover of HKD 118 million. The stock advanced amid a broad CXO sector rally that lifted the entire Life Sciences Tools & Services space.

On the news front, the CXO sector exhibited strong collective momentum, with peers WuXi Bio up 5.33%, Pharmaron up 7.17%, WuXi AppTec up 3.65%, and XtalPi up 13.33%, reflecting pronounced sector resonance. BOCOM International recently highlighted WuXi XDC as a top pick among high-prosperity track leaders with attractive investment value. The company's previously announced share repurchase plan of up to USD 100 million, along with AGM-approved authorization to buy back up to 10% of issued shares, continues to provide price support. Multiple institutions have noted the sector's entry into a new prosperity cycle, with CXO companies reporting robust order backlogs and accelerating revenue conversion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)